Every specialty consolidation wave in American medicine has followed the same pattern. Independent practices dominate the specialty, with most physicians owning their practices and consolidators not yet arrived. Most institutional capital considers the category too small, too fragmented, or too specialized to pursue. Eventually early operators arrive: small platforms form, often with physician-entrepreneur founders, practices begin consolidating in regional markets, and institutional capital observes but doesn't participate meaningfully because deal sizes are sub-scale and investment theses aren't yet institutionalized. Then institutional capital floods in: multiple PE platforms form simultaneously, transaction multiples expand rapidly, consolidation accelerates, early operators exit at premium multiples, and later capital arrives at higher entry prices. Finally consolidation matures: the category becomes dominated by a few large platforms, strategic corporate acquirers absorb the trophy platforms, remaining fragmented opportunity shrinks, and institutional capital that missed the early phases now faces limited entry points at compressed expected returns.

American dental, veterinary, and dermatology all followed this pattern. Institutional capital participated heavily in the late phases, early-phase operators captured outsized returns, and the institutional capital that arrived after multiples had expanded paid progressively higher prices as the category matured. American ophthalmology in 2026 sits in the early-operator phase, with the institutional flood-in transition constrained by the broader healthcare PE fundraising collapse and exit environment weakness that other specialties didn't face at comparable stages. Institutional capital that waits for the institutional flood-in to validate the ophthalmology opportunity may find, as it did in veterinary and dental before, that the best entry points were before the flood arrived.

The Patterns That Already Played Out

American dental consolidation moved fast once it started. Dental service organizations (DSOs) controlled 7.2% of US dental practices in 2015 per industry data, and by 2024, DSO share had climbed to 16.1%, with L.E.K. Consulting projecting approximately 39% DSO market share by 2026. Heartland Dental, the largest single DSO platform, provides a cleaner benchmark. Rick Workman founded Heartland Dental in 1997, Ontario Teachers' Pension Plan acquired a majority stake in November 2012 at approximately $1.3 billion enterprise value (representing roughly 11x trailing EBITDA), and between 2012 and 2018 Heartland scaled from approximately 397 offices to 840+ offices. KKR acquired a majority stake in April 2018 at a substantially higher multiple than OTPP's 2012 entry. The exact transaction value wasn't publicly disclosed, and market sources reported the multiple expansion was significant. Institutional capital that entered dental in 2012 (OTPP) generated substantial returns by 2018; institutional capital that entered in 2018 (KKR) paid materially higher prices for the same asset category. The compounding entry multiple tells the pattern.

American veterinary consolidation followed similar mechanics. VCA Animal Hospitals, the largest US veterinary platform, was acquired by Mars Inc. in January 2017 for $9.1 billion at approximately 19x trailing EBITDA. National Veterinary Associates was acquired by JAB Holding in June 2019 at comparable valuation, and JAB subsequently added Ethos Veterinary Health for $1.65 billion in 2021 and Sage Veterinary for $1.1 billion in 2022. Silver Lake acquired Southern Veterinary Partners (merged with Mission Veterinary Partners) in early 2024 at approximately $8.6 billion and 14.8x EBITDA for 750+ locations combined. At the individual practice level, general practice veterinary multiples expanded from 7-8x in 2021 to 8-12x by 2022, specialty veterinary platforms trade in the high-teens to low-20s EBITDA multiples, and at least one reported transaction hit 26.5x in 2022. Roughly $45 billion of PE capital flowed into veterinary consolidation between 2017 and 2022 per Private Equity Stakeholder Project analysis, and the category moved from fragmented to majority-consolidated within approximately 7 years of institutional capital's serious entry.

American dermatology consolidation followed the same arc. Forefront Dermatology's trajectory illustrates the derm pattern: Varsity Healthcare Partners acquired Forefront in 2012, by 2016 Forefront had scaled from 37 to 82 locations under Varsity's ownership, OMERS Private Equity acquired Forefront from Varsity in January 2016 at greater than $450 million enterprise value, and Audax acquired Advanced Dermatology and Cosmetic Surgery (ADCS) in May 2016. By 2017, approximately 1 in 11 dermatologists practiced inside a PE-acquired group per Health Affairs research, over 245 dermatology practices had been acquired by PE platforms by 2021, and the specialty now has 35-40 PE platforms operating with 85 practice acquisitions in 2023 alone. Dermatology entry multiples expanded from roughly 6x for early platform acquisitions in 2014 to double-digit multiples by 2018-2022 for established platforms, and institutional capital that entered early captured substantial multiple expansion.

The Pass Reasons Repeated

Institutional capital passed on dental, veterinary, and dermatology at the early stages for directly parallel reasons. The dental pass reasons through 2010 ran along the lines of "commodity service, too fragmented, low margins, consumer-pay exposure, recession-sensitive." Every one of those concerns was directionally accurate: dentistry is more fragmented than most institutional investors wanted to underwrite, margins are modest relative to specialty medical, recession exposure exists through elective dental care, and the concerns weren't wrong. What made the concerns irrelevant to the investment thesis was hygienist-driven predictable cash flow, demographic stability (tooth care demand doesn't fluctuate with economic cycles as much as initially feared), and operating leverage at scale that enabled margin expansion as platforms grew. OTPP's Heartland entry in 2012 looked expensive to early institutional observers who were focused on the pass reasons; by 2018, that entry had compounded substantially.

The veterinary pass reasons through 2015 ran along the lines of "niche, out-of-pocket pay exposes recession risk, pet care demand unreliable, specialty too narrow for institutional scale." Every concern was directionally accurate: pet care is largely out-of-pocket in the United States, veterinary demand does respond to economic conditions, and the specialty was narrower than general healthcare. What made the concerns irrelevant was pet humanization trends (pets increasingly treated as family members, with spending to match), recession resilience that proved stronger than initial models predicted, and specialty compounding through subspecialty verticals (emergency, cardiology, oncology) that institutional capital hadn't previously modeled at scale. Mars's VCA acquisition in 2017 looked expensive at the time; by 2022, the category was absorbing billions of additional capital at comparable or higher multiples.

The dermatology pass reasons through 2014 ran along the lines of "too fragmented, physician-dependent, elective demand exposure, high regulatory risk around Mohs and cosmetics." Each concern had merit: dermatology was more fragmented than some comparable specialties, physician retention was genuinely challenging, and certain procedure categories face reimbursement pressure. What made the concerns irrelevant was Mohs surgery economics (extremely high margin procedure with stable reimbursement), pathology integration (dermatopathology is a parallel revenue stream that scales with practice volume), cosmetic services (cash-pay ancillary revenue), and operational efficiencies at scale. Varsity at 6x in 2012 and OMERS in 2016 both generated strong returns despite the early-stage concerns. The repeating pattern is direct: institutional capital passes on specialty consolidation opportunities for concerns that turn out to be irrelevant to the investment thesis, then pays substantially higher multiples when the thesis institutionalizes.

The Ophthalmology Pass Reasons in 2026

Institutional capital's current reasons for limited engagement with the ophthalmology opportunity in 2026 are documented in capital-raise conversations, allocator memos, and industry commentary. The most common is that "EyeCare Partners' 2024 restructuring proves the model doesn't work." EyeCare Partners' April-May 2024 out-of-court liability management exercise involved first-lien debt trading at approximately 54 cents on the dollar before restructuring, with Partners Group and lenders injecting $275 million of super-priority capital and maturities extended to 2027. The structural counter is that EyeCare Partners' problem was its capital structure, not ophthalmology practice economics; EyeCare Partners was capitalized with leverage appropriate for a fund-cycle exit model, and when the exit environment weakened and Medicare reimbursement was cut, the debt service requirement became unsustainable against the operational cash flow. That's a capital structure failure, not a category failure. The underlying practices within EyeCare Partners continue to generate patient volume and practice-level cash flow at levels consistent with the category's economic characteristics.

A second pass reason is "macro and interest rate headwinds for healthcare consolidation." Deal volume in ophthalmology dropped from 300+ transactions in 2021 to under 100 in 2025 per VMG Health analysis, and the broader healthcare PE fundraising environment collapsed to $9.5 billion in H1 2025 across 10 funds (more than half to Linden VI alone). The structural counter is that the macro and interest rate environment creates entry opportunities for capital that doesn't depend on debt financing or fund-cycle exits: patient capital operators deploying direct equity face less competition from levered PE buyers in a tightened debt environment, and the compression of transaction multiples from the 2021 peak (12-16x platform / 10-12x add-on) to current levels (10-15x platform / 6-10x add-on / 5-8x solo-smaller) creates entry opportunity for capital that's positioned for lower multiples.

A third pass reason is "federal regulatory scrutiny of specialty PE consolidation." The Senate Budget Committee "Profits Over Patients" report in January 2025 documented PE-induced clinical quality issues, FTC consent orders on PE healthcare transactions have tightened, and multiple states (Oregon SB 951, California, Washington, New Mexico, Colorado, Massachusetts, Maine) have tightened corporate practice of medicine (CPOM) requirements in 2025. The structural counter is that the regulatory tightening specifically targets PE-model consolidation structures that prioritize extraction over clinical quality. Patient-capital operators running physician-led platforms with physician ownership retention, transparent governance, and long-horizon operational focus sit on the opposite side of the regulatory concern, and tightened CPOM and FTC scrutiny creates regulatory moats that favor physician-aligned platforms over extractive PE structures.

A fourth pass reason is "Medicare reimbursement pressure." The 2.83% Medicare PFS cut in FY25 and the projected 11% cataract cut in 2026 create ongoing reimbursement pressure. The structural counter is that reimbursement pressure applies to every capital class equally, and what differs is the capital structure's ability to absorb and adjust. PE platforms with leveraged capital structures have less operational flexibility to absorb reimbursement cuts without compromising clinical operations, while patient-capital operators with no leverage pressure can absorb reimbursement cycles and reinvest across demographic tailwinds that continue to drive procedural volume growth independent of unit-price pressure.

A fifth pass reason is that "physician culture is incompatible with scale," a position American Journal of Ophthalmology 2024 commentary from Gilligan & Bettinger argued when noting that ophthalmology's physician culture may resist large-scale consolidation. The structural counter is that physician culture resists certain types of consolidation more than others. Physicians specifically resist consolidation that compromises clinical autonomy, imposes productivity metrics aligned with fund returns rather than patient care, and converts physician-owners into employees. Physicians are more accepting of consolidation structures that preserve clinical autonomy, maintain physician governance participation, and operate at capital-structure time horizons consistent with physician career arcs. Patient-capital platforms structured around these principles face different physician reception than PE platforms structured around fund-cycle optimization.

Every one of the 2026 pass reasons for ophthalmology is directionally accurate as a concern, and every one of them turns out to be irrelevant to the patient-capital investment thesis the same way the dental, veterinary, and dermatology pass reasons were irrelevant to the investment theses that generated strong returns in those specialties.

What History Predicts

The pattern of institutional capital entering specialty consolidation late and paying for it isn't unique to healthcare. Similar patterns exist across franchise consolidation (Roark Capital building to $37 billion AUM and $52 billion in system sales), auto dealership consolidation (public dealer groups now represent roughly 7% of new vehicle sales), and physical therapy consolidation (still fragmented but tightening). The specific mechanic: specialty categories that produce durable cash flow, face demographic tailwinds, and have fragmented ownership structures consolidate over 10-20 year periods. Early capital that enters at modest entry multiples compounds strongly, while late capital that enters after the multiples have expanded pays progressively higher prices and faces compressed expected returns.

Ophthalmology in 2026 has the early-operator characteristics visible in dental (2010-2014), veterinary (2012-2016), and dermatology (2012-2015): fragmented ownership (70.4% independent), demographic tailwinds (cataract volume growing, AMD and DR prevalence rising sharply through 2050), durable unit economics (AAOE benchmarks documenting strong cash flow margins), and limited but growing institutional competition (40 PE platforms operating, most in stabilization or forced-seller mode rather than aggressive growth). The historical pattern suggests ophthalmology's institutional capital flood will arrive over the next 3-7 years as the broader healthcare PE fundraising environment recovers or as strategic corporate acquirers expand their specialty-acquisition budgets beyond retina and top-tier platforms. Entry multiples after that flood will be higher than entry multiples now. Capital that enters in 2026-2028 at current multiples will see multiple expansion as institutional competition arrives; capital that waits for institutional validation will pay for the validation.

That's the structural pattern that has repeated across every specialty consolidation wave in American physician services for two decades. It's the pattern that dental, veterinary, and dermatology played out, and American ophthalmology in 2026 fits the same early-phase characteristics that generated the best returns in those earlier specialty waves. The institutional capital that missed dental in 2012, veterinary in 2015, and dermatology in 2014 is structurally likely to miss ophthalmology in 2026 for exactly the same reasons: pass decisions based on directionally-accurate concerns that turn out to be irrelevant to the investment thesis. The capital class that enters ophthalmology now is the same class that entered the earlier specialties at their most attractive entry points.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com